ERBB2 and cholangiocarcinoma: Of these, 25% (17/69), 4% (5/133), and 7% (6/82) were HER2‐positive, respectively, and 20 patients (UBC, n = 13; pancreatic cancer, n = 4; cholangiocarcinoma, n = 3) met all eligibility criteria (Figure 1).